NOISEReport
Coverage history

Assembled by NOISE.

Report / Business

Published by NOISE

Eli Lilly raises outlook after beating estimates on Zepbound, Mounjaro demand

From Morning NOISE.

Eli Lilly beat third-quarter expectations and raised its full-year 2026 revenue forecast to between $91 billion and $92 billion, up from $85 billion to $87 billion. Adjusted earnings were $7.48 per share on revenue of $24.40 billion, above analyst forecasts. Demand drove Mounjaro sales up 65% to $10.72 billion and Zepbound sales up 49% to $5.35 billion, though the new obesity pill Foundayo brought in $184 million, below expectations. The results show Lilly's GLP-1 franchise remains strong despite lower US prices and competition from Novo Nordisk.

Saved versions

These dates record changes to NOISE’s copy. They are not event dates.

  1. Retained copyCurrentIn saved edition